Steve Oghumu

Dr. Steve Oghumu

Department of Pathology, College of Medicine, 337 Hamilton Hall, 1645 Neil Ave, Columbus, OH 43210, USA
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2015 in Molecular Oncology
Verified
Journal Article
Open access
MEMohamad Elbaz
Mohamad Elbaz
Mohd NasserMohd Nasser
Mohd Nasser
JRJanani Ravi
Janani Ravi
NWNissar Ahmad Wani
Nissar Ahmad Wani
DADinesh Kumar Ahirwar
Dinesh Kumar Ahirwar
Ramesh k GanjuRamesh k Ganju
Ramesh k Ganju
The anti‐tumor role and mechanisms of Cannabidiol (CBD), a non‐psychotropic cannabinoid compound, are not well studied especially in triple‐negative breast cancer (TNBC). In the present study, we analyzed CBD's anti‐tumorigenic activity against highly aggressive breast cancer cell lines including TNBC subtype. We show here ‐for the first time‐that CBD significantly inhibits epidermal growth factor (EGF)‐induced proliferation and chemotaxis of breast cancer cells. Further studies revealed that CBD inhibits EGF‐induced activation of EGFR, ERK, AKT and NF‐kB signaling pathways as well as MMP2 and MMP9 secretion. In addition, we demonstrated that CBD inhibits tumor growth and metastasis in different mouse model systems. Analysis of molecular mechanisms revealed that CBD significantly inhibits the recruitment of tumor‐associated macrophages in primary tumor stroma and secondary lung metastases. Similarly, our in vitro studies showed a significant reduction in the number of migrated RAW 264.7 cells towards the conditioned medium of CBD‐treated cancer cells. The conditioned medium of CBD‐treated cancer cells also showed lower levels of GM‐CSF and CCL3 cytokines which are important for macrophage recruitment and activation. In summary, our study shows ‐for the first time‐that CBD inhibits breast cancer growth and metastasis through novel mechanisms by inhibiting EGF/EGFR signaling and modulating the tumor microenvironment. These results also indicate that CBD can be used as a novel therapeutic option to inhibit growth and metastasis of highly aggressive breast cancer subtypes including TNBC, which currently have limited therapeutic options and are associated with poor prognosis and low survival rates.

29 November 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
NRNathan Ryan
Nathan Ryan
KAKelvin Anderson
Kelvin Anderson
GVGreta Volpedo
Greta Volpedo
OHOmar Hamza
Omar Hamza
SVSanjay Varikuti
Sanjay Varikuti
Steve OghumuSteve Oghumu
Steve Oghumu

15 August 2019 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
Steve OghumuSteve Oghumu
Steve Oghumu
SVSanjay Varikuti
Sanjay Varikuti
JSJames C. Stock
James C. Stock
GVGreta Volpedo
Greta Volpedo
NSNoushin Saljoughian
Noushin Saljoughian
Abhay SatoskarAbhay Satoskar
Abhay Satoskar
CXCR3, an X-linked gene, is subject to X chromosome inactivation (XCI), but it is unclear whether CXCR3 escapes XCI in immune cells. We determined whether CXCR3 escapes XCI in vivo, evaluated the contribution of allelic CXCR3 expression to the phenotypic properties of T cells during experimental infection with Leishmania, and examined the potential implications to sex differences in immune responses. We used a bicistronic CXCR3 dual-reporter mouse, with each CXCR3 allele linked to a green or red fluorescent reporter without affecting endogenous CXCR3 expression. Our results show that CXCR3 escapes XCI, biallelic CXCR3-expressing T cells produce more CXCR3 protein than monoallelic CXCR3-expressing cells, and biallelic CXCR3-expressing T cells produce more IFN-γ, IL-2, and CD69 compared with T cells that express CXCR3 from one allele during Leishmania mexicana infection. These results demonstrate that XCI escape by CXCR3 potentially contributes to the sex-associated bias observed during infection. Key Points A bicistronic dual-reporter mouse enables visualization of allelic CXCR3 expression. CXCR3 escapes X chromosome inactivation (XCI) in T cells in vivo during infection. XCI escape by CXCR3 potentially contributes to enhanced Th1 responses in females.

11 July 2019 in Metabolites
Verified
Journal Article
Open access
PDF file
TKThomas Knobloch
Thomas Knobloch
NRNathan Ryan
Nathan Ryan
LBLei Bruschweiler-Li
Lei Bruschweiler-Li
Cheng WangCheng Wang
Cheng Wang
MBMatthew C. Bernier
Matthew C. Bernier
Steve OghumuSteve Oghumu
Steve Oghumu
Oral cancer is a public health problem with an incidence of almost 50,000 and a mortality of 10,000 each year in the USA alone. Black raspberries (BRBs) have been shown to inhibit oral carcinogenesis in several preclinical models, but our understanding of how BRB phytochemicals affect the metabolic pathways during oral carcinogenesis remains incomplete. We used a well-established rat oral cancer model to determine potential metabolic pathways impacted by BRBs during oral carcinogenesis. F344 rats were exposed to the oral carcinogen 4-nitroquinoline-1-oxide in drinking water for 14 weeks, then regular drinking water for six weeks. Carcinogen exposed rats were fed a 5% or 10% BRB supplemented diet or control diet for six weeks after carcinogen exposure. RNA-Seq transcriptome analysis on rat tongue, and mass spectrometry and NMR metabolomics analysis on rat urine were performed. We tentatively identified 57 differentially or uniquely expressed metabolites and over 662 modulated genes in rats being fed with BRB. Glycolysis and AMPK pathways were modulated during BRB-mediated oral cancer chemoprevention. Glycolytic enzymes Aldoa, Hk2, Tpi1, Pgam2, Pfkl, and Pkm2 as well as the PKA-AMPK pathway genes Prkaa2, Pde4a, Pde10a, Ywhag, and Crebbp were downregulated by BRBs during oral cancer chemoprevention. Furthermore, the glycolysis metabolite glucose-6-phosphate decreased in BRB-administered rats. Our data reveal the novel metabolic pathways modulated by BRB phytochemicals that can be targeted during the chemoprevention of oral cancer.

23 October 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
Steve OghumuSteve Oghumu
Steve Oghumu
BCBruce C. Casto
Bruce C. Casto
JAJennifer Ahn-Jarvis
Jennifer Ahn-Jarvis
LWLogan C. Weghorst
Logan C. Weghorst
JMJim Maloney
Jim Maloney
TKThomas Knobloch
Thomas Knobloch
Oral cancer continues to be a significant public health problem worldwide. Recently conducted clinical trials demonstrate the ability of black raspberries (BRBs) to modulate biomarkers of molecular efficacy that supports a chemopreventive strategy against oral cancer. However, it is essential that a preclinical animal model of black raspberry (BRB) chemoprevention which recapitulates human oral carcinogenesis be developed, so that we can validate biomarkers and evaluate potential mechanisms of action. We therefore established the ability of BRBs to inhibit oral lesion formation in a carcinogen-induced rat oral cancer model and examined potential mechanisms. F344 rats were administered 4NQO (20μg/ml) in drinking water for 14 weeks followed by regular drinking water for 6 weeks. At week 14, rats were fed a diet containing either 5% or 10% BRB, or 0.4% percent ellagic acid (EA), a BRB phytochemical. Dietary administration of 5% and 10% BRB reduced oral lesion incidence and multiplicity by 39.3% and 28.6% respectively. Histopathological analyses demonstrate the ability of BRBs and, to a lesser extent EA, to inhibit the progression of oral cancer. Oral lesion inhibition by BRBs was associated with a reduction in the mRNA expression of pro-inflammatory biomarkers Cxcl1, Mif and Nfe2l2 as well as the anti-apoptotic and cell cycle associated markers Birc5, Aurka, Ccna1 and Ccna2. Cellular proliferation (Ki-67 staining) in tongue lesions was inhibited by BRBs and EA. Our study demonstrates that, in the rat 4NQO oral cancer model, dietary administration of BRBs inhibits oral carcinogenesis via inhibition of pro-inflammatory and anti-apoptotic pathways.

10 May 2016 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
Steve OghumuSteve Oghumu
Steve Oghumu
TKThomas Knobloch
Thomas Knobloch
CTCesar Terrazas
Cesar Terrazas
SVSanjay Varikuti
Sanjay Varikuti
JAJennifer Ahn‐Jarvis
Jennifer Ahn‐Jarvis
Abhay SatoskarAbhay Satoskar
Abhay Satoskar